<DOC>
	<DOCNO>NCT01058291</DOCNO>
	<brief_summary>This placebo-controlled double-blind crossover comparative study KW-6500 Parkinson 's disease patient motor response complication levodopa therapy . The efficacy KW-6500 evaluate use change UPDRS part III score double blind period 12 week subcutaneous self-injections .</brief_summary>
	<brief_title>Placebo-Controlled Double-Blind Crossover Comparative Study KW-6500</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients give write informed consent Patients Parkinson 's disease Patients stable regimen levodopa plus least one antiparkinsonian agent OFF state Patients meet stage 4 5 OFF state stage 0 3 ON state Modified Hoehn Yahr Scale Patients experience 30 % improvement Unified Parkinson 's Disease Rating Scale ( UPDRS ) partâ…¢ score test responsiveness levodopa baseline period Patients least one OFF state per day Patients understand expression OFF state , ON state , dyskinesia Patients family desire selfinjection KW6500 Patients illness cardiac , hematologic , hepatic , renal , pancreatic , metabolic , respiratory , gastrointestinal , endocrinologic , neurologic system ( exclude Parkinson 's disease ) Patients orthostatic hypotension Patients history intolerance morphine derivative , sulfur , sulfurcontaining pharmaceutical product , sulfite Patients history malignant syndrome Patients diagnosis cancer evidence continue disease Patients test negative direct Coombs ' test Pregnant lactating woman , woman plan child , woman test positive pregnancy test , woman adhere reliable method contraception Patients receive MAO inhibitor except selegiline Patients history mental disease ( exclude psychiatric symptom associate Parkinson 's disease ) Patients MiniMental State Examination score 23 less Patients take antipsychotics central dopamine antagonist ( exclude domperidone ) Patients receive methyldopa 5HT3 receptor antagonist Patients receive reserpine papaverine Patients neurosurgical operation Parkinson 's disease Patients transcranial magnetic stimulation Patients history drug alcohol abuse dependence</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>